Prolonged Survival in an Elderly Patient with CD4+ CD56+ Lymphoma of the Skin with Autologous Peripheral Blood Stem Cell Transplantation (PBSCT).

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5493-5493
Author(s):  
Rajneesh Nath ◽  
Stephen M. Abo

Abstract CD4+ CD56+ lymphomas are recently described rare hematological neoplasms thought to be originating from plasmacytoid dendritic cells. Clinical features typically include cutaneous nodules associated with lymphadenopathy and/or splenomegaly and bone marrow involvement during the disease course. Complete remission (CR) is frequently obtained (around 80%) with polychemotherapy. However, median time to relapse is about 9 (range 3–18) months and median survival is only 13 months. Age > 60 years is a poor prognostic factor. Long term survival has only been reported following allogeneic SCT (Bone Marrow Transplantation32, 637–646, 2003; Blood99,1556–1563, 2002). We report a case of CD4+ CD56 + lymphoma with prolonged survival after an autologous PBSCT. A 71-year-old male presented in the fall of 2001 with facial erythema that progressed to several purple cutaneous nodules also involving his trunk. Skin biopsy done in June 2002 confirmed the diagnosis of CD4+ CD56+ lymphoma of the skin. Staging studies including CT scan of the chest, abdomen and pelvis, and bone marrow aspiration and biopsy were negative. The patient received chemotherapy with CHOPE (cytoxan 750 mg/m2, adriamycin 50 mg/m2, vincristine 1.4 mg/2, prednisone 100mg x 5 days, etoposide 120 mg/m2) for six cycles starting June 2002, and achieved a CR with disappearance of all skin lesions. CT scan of the chest pretransplant revealed a single 2 cm paratracheal lymph node that was also PET positive. Stem cells were collected using cytoxan 4 gms/m2 followed by 10 mcg/kg/day of G-CSF. The patient underwent autologous stem cell transplantation in February 2003 using BEAM (carmustine 300mg/m2 day −6, etopside 200mg/2 days −5 to −2, cytarabine 400mg/m2 days −5 to −2, melphalan 140 mg/m2 day -1) as a preparative regimen. Neutrophil engraftment occurred on day 10 and platelets engrafted on day 14 post SCT. The paratracheal lymph node was still visible on the PET scan 6 months post SCT. However, restaging studies at one year and beyond have all been negative for disease reoccurrence including a CT chest that revealed a calcified paratracheal lymph node that was negative on PET scan. The patient continues to be in complete remission 37 months from diagnosis and 30 months post SCT. The aggressive nature of CD4+ CD56+ lymphoma is evident by its 9-month median time to relapse and short survival. Therefore, aggressive treatment protocols incorporating stem cell transplant should be utilized in their management and should not be limited to only younger patients. As illustrated by our patient, the use of autologous stem cell transplant in the elderly can be done safely with encouraging results.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e18503-e18503
Author(s):  
Brian Pham ◽  
Rasmus Hoeg ◽  
Nisha Hariharan ◽  
Kathyryn Alvarez ◽  
Aaron Seth Rosenberg ◽  
...  

e18503 Background: There is no standard treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) relapsing after allogeneic stem cell transplant (SCT). Options include combination chemotherapy, withdrawal of immunosuppression, donor lymphocyte infusion (DLI), and second SCT. Previous studies have used fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG) or second SCT separately for salvage therapy. Our institution uses FLAG followed by SCT from the same donor (FLAG/SCT) in this setting. We report a retrospective study of FLAG/SCT in MDS and AML patients relapsed after SCT. Methods: Patients who received FLAG/SCT for treatment of relapsed AML or MDS between 2009 and 2018 were identified using the bone marrow transplant database at University of California Davis. Their baseline characteristics and outcomes were determined using the electronic medical record. Descriptive statistics and Kaplan-Meier survival analysis were used to describe patients, rates of graft-versus-host disease (GvHD) and estimate survival times. Results: Nineteen patients received FLAG/SCT for AML (n=18) and MDS (n=1). Median time to relapse from first SCT was 145 days (range 41 to 960 days). Prior to FLAG/SCT, 17 patients had medullary relapse (median bone marrow blasts 27%; range 7-85%). Two patients had extramedullary relapse. Eighteen (94.7%) patients achieved complete remission (CR) after FLAG/SCT. Median follow-up time was 354 days from the first day of FLAG/SCT (range 7 to 2144 days). Six patients (31.6%) relapsed with median time to relapse of 334 days (range 78 to 679 days) after treatment. Overall survival at 2 years was 52.5%. Causes of death were relapsed AML (n=4; 21.1%), infection (n=4; 21.1%) complications of GvHD (n=3,15.8 %), and brain herniation (n=1, 5.3%). Acute GvHD grade I-IV and new onset chronic GvHD occurred in thirteen (68.4%) and eight patients (42.1%), respectively. Conclusions: FLAG/SCT for AML and MDS relapsing after SCT resulted in a high remission rate. The overall survival of over two years suggests that the second SCT augmented the graft versus leukemia effect. The GvHD rate increased after second SCT, but the rate and severity were manageable. FLAG/ SCT is a reasonable option for relapsed AML and MDS after SCT.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4603-4603
Author(s):  
Mohamad Ali Cherry ◽  
William Kern ◽  
Benjamin Wagenman ◽  
Robert B. Epstein ◽  
Kris Kratochvil ◽  
...  

Abstract Abstract 4603 Introduction: Successful transplantation of cryopreserved hematopoietic stem cell (HSC) can be regularly achieved provided sufficient numbers of cells are administered. However the optimal conditions for preparation, freezing and thawing remain to be defined. The duration of hematopoietic stem cell viability is unclear. The ultimate measure of viability has remained in vivo hematologic recovery following transplantation. Evidence of autologous repopulation in preclinical setting has been seen at 14 years after bone marrow transplant and after 12 years in the clinical setting after peripheral stem cell transplant. We report a successful transplantation in a patient in whom autologous cryopreserved marrow with cellular dose of 1.21 × 108/kg was infused 21 years following collection. Case: The patient is 43 year old man found to have follicular lymphoma with bone marrow involvement in 1989 at age 22. He achieved complete remission after treatment with two cycles of Chorambucil. Bone marrow procurement and cryopreservation was performed at that time for possible subsequent infusion. The procured marrow consisted of a total cell count of 1.21 × 10^8 cells/per kg body wt with a total volume of 354 ml. Equal parts of 20% DMSO were combined with marrow to a final concentration of 10% DMSO. The marrow was then stored in the liquid phase of nitrogen from date of collection until date of infusion 21 years later. Our patient relapsed in 1996, and eventually underwent treatment in 2006 with six cycles of Fludarabine and Rituximab, achieving a complete remission. He continued Rituximab therapy maintenance every 6 months for a total of 2 years. During Rituximab therapy, he was noted to have pancytopenia Work-up confirmed MDS with 5q- and translocation of long arm of chromosome 6q21 and short arm 17p13 in 20/20 cells by karyotype analysis. Patient elected to proceed with the cryopreserved marrow transplant. Assessment of cryopreserved marrow for dysplasia was undertaken showing no evidence of cytogenetic or histological changes. The patient was prepared with Busulfan IV at 0.8/kg q 6 hours × 4 days and Cyclophosphamide 60mg/kg IV × 2 days. The marrow was infused 21 years following its procurement. Samples from the infused marrow showed 65–75% viability by Tryptan blue assay. White cell engraftment occurred on day 17 and platelet reached 20,000 by day 30. Follow-up 2 months post transplant revealed persistent mild pancytopenia, WBC of 2.6 with ANC 1500, Hgb 9.8 and platelets of 43,000. FISH analysis for 5q performed showed 85/200 cells positive for 5q-. Bone marrow biopsy confirmed dysplastic features consistent with his pre-transplant bone marrow biopsy. Our case illustrates that even in the setting of marginal numbers of infused marrow components and after prolonged cryopreservation, repopulation can readily occur. However, inability to eliminate the malignant clone following stable engraftment brings to light both the necessity of adequate ablation in pretransplant conditioning, and the importance of graft-versus-tumor effect in marrow born malignancies. To our knowledge, this is the oldest successful cryopreserved autologous bone transplant at 21 years post preservation. As novel uses of stem cells advance, optimal storage of various cellular components is necessary. This should be further investigated on a larger scale in the future. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 4790-4790
Author(s):  
Moazzam Shahzad ◽  
Muhammad Arslan ◽  
Zehra Naseem ◽  
Sakina Abbas ◽  
Naira Fatima ◽  
...  

Abstract Background: Research performance is evaluated by bibliometric analysis of citations, and this can help to identify the most impactful articles in the field of hematopoietic stem cell transplantation (HSCT). We conducted a bibliometric analysis to identify scholarly impact and factors associated with the top 100 cited articles on HSCT. Methods: Thomas Reuters Web of Science core collection (WoS) was accessed in January 2021 and a title-specific search was conducted using the keywords "hematopoietic stem-cell transplantation ", "transplantation, hematopoietic stem cell," "stem cell transplantation, hematopoietic," "bone-marrow transplantation," "transplantation, bone marrow," "grafting, bone marrow," "transplantation bone marrow cell," "bone marrow cell transplantation," "stem cell transplant," "allogeneic hematopoietic stem cell transplant," "autologous hematopoietic stem cell transplant". Non-Human and non-HSCT studies were excluded. A total of 39,406 records were identified and a list of the top 100 articles was made. Articles included in our study were characterized by the number of citations, year of publication, topic, study design, authors, h-index, and institutions. Data were analyzed using SPSS in April 2021. Bivariate analyses, using chi-square and t-test, and linear regression analyses were performed. Results: The 100 most cited articles in the field were published over 52 years from 1968 to 2020, with a maximum number of articles (n=40) published in the 1990s decade. Top-100 articles were cited 62,002 times with a median citation count of 465 (range 336-2240). The top-cited articles originated from 12 countries and the United States (US) contributed 69 articles. The University of Washington Fred Hutchinson Cancer Center (n=15) was the leading institution. Blood (n=32) and New England Journal of Medicine (n=31) made the greatest contribution, and 41 manuscripts were clinical trials. In a multivariate regression model, the first author's h-index (regression coefficient 5.46, 95% confidence interval 2.99-7.93, p<0.001) correlated with the citation count while gender, journal impact factor, years since publication, and the number of authors did not have a significant association. Conclusion: Our study highlights the most influential articles on clinical HSCT, centralization of research to North American and European institutions, and provides valuable insight for future research needs of the specialty. Figure 1 Figure 1. Disclosures Abhyankar: Incyte/Therakos: Consultancy, Research Funding, Speakers Bureau. McGuirk: Novartis: Research Funding; Pluristem Therapeutics: Research Funding; Juno Therapeutics: Consultancy, Honoraria, Research Funding; Astelllas Pharma: Research Funding; Magenta Therapeutics: Consultancy, Honoraria, Research Funding; Allovir: Consultancy, Honoraria, Research Funding; Gamida Cell: Research Funding; EcoR1 Capital: Consultancy; Bellicum Pharmaceuticals: Research Funding; Novartis: Research Funding; Fresenius Biotech: Research Funding; Kite/ Gilead: Consultancy, Honoraria, Other: travel accommodations, expense, Kite a Gilead company, Research Funding, Speakers Bureau.


2004 ◽  
Vol 22 (14) ◽  
pp. 2816-2825 ◽  
Author(s):  
Michael G. Kiehl ◽  
Ludwig Kraut ◽  
Rainer Schwerdtfeger ◽  
Bernd Hertenstein ◽  
Mats Remberger ◽  
...  

Purpose The role of unrelated allogeneic stem-cell transplantation in acute lymphoblastic leukemia (ALL) patients is still not clear, and only limited data are available from the literature. We analyzed factors affecting clinical outcome of ALL patients receiving a related or unrelated stem-cell graft from matched donors. Patients and Methods The total study population was 264 adult patients receiving a myeloablative allogeneic stem-cell transplant for ALL at nine bone marrow transplantation centers between 1990 and 2002. Of these, 221 patients receiving a matched related or unrelated graft were analyzed. One hundred forty-eight patients received transplantation in complete remission; 62 patients were in relapse; and 11 patients were refractory to chemotherapy before transplant. Fifty percent of patients received bone marrow, and 50% received peripheral blood stem cell from a human leukocyte antigen–identical related (n = 103), or matched unrelated (n = 118) donor. Results Disease-free survival (DFS) at 5 years was 28%, with 76 patients (34%) still alive (2.2 to 103 months post-transplantation), and 145 deceased (65 relapses, transplant-related mortality, 45%). We observed an advantage regarding DFS in favor of patients receiving transplantation during their first complete remission (CR) in comparison with patients receiving transplantation in or after second CR (P = .014) or who relapsed (P < .001). We observed a clear trend toward improved survival in favor of B-lineage ALL patients compared with T-lineage ALL patients (P = .052), and Philadelphia chromosome–positive patients had no poorer outcome than Philadelphia chromosome–negative patients. Total-body irradiation–based conditioning improved DFS in comparison with busulfan (P = .041). Conclusion Myeloablative matched related or matched unrelated allogeneic hematopoietic stem-cell transplantation in ALL patients should be performed in first CR.


2002 ◽  
Vol 20 (7-8) ◽  
pp. 893-903 ◽  
Author(s):  
Deborah B. McGuire ◽  
Douglas E. Peterson ◽  
Susan Muller ◽  
Donna C. Owen ◽  
Marina F. Slemmons ◽  
...  

2020 ◽  
Vol 106 (6) ◽  
pp. NP5-NP8
Author(s):  
Matteo Carella ◽  
Vittorio Stefoni ◽  
Cinzia Pellegrini ◽  
Lisa Argnani ◽  
Michele Cavo ◽  
...  

Background: Follicular lymphoma (FL) is characterized by frequent relapses and need for multitude lines of therapy, which includes different immunochemotherapy regimens, novel monoclonal antibodies, novel drugs, and autologous or allogenic stem cell transplant. Early use of autologous stem cell transplantation (ASCT) improves prognosis in patients with FL who may be candidates for an aggressive approach. Case presentation: We report the case of a 49-year-old woman with thrombophilia with relapsed/refractory grade 3A FL, heavily pretreated, who achieved third complete remission after high-dose chemotherapy and ASCT, despite experiencing life-threatening adverse events during her treatment history. Conclusions: Stem cell transplantation has emerged as the standard of care for young patients with FL but may be effective also in complex and multirelapsed clinical cases.


Sign in / Sign up

Export Citation Format

Share Document